Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol
Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol
Purpose: to prospectively validate two risk scores to predict mortality (4C Mortality) and in-hospital deterioration (4C Deterioration) among adults hospitalised with COVID-19.
Methods: prospective observational cohort study of adults (age ≥18 years) with confirmed or highly suspected COVID-19 recruited into the International Severe Acute Respiratory and emerging Infections Consortium (ISARIC) WHO Clinical Characterisation Protocol UK (CCP-UK) study in 306 hospitals across England, Scotland and Wales. Patients were recruited between 27 August 2020 and 17 February 2021, with at least 4 weeks follow-up before final data extraction. The main outcome measures were discrimination and calibration of models for in-hospital deterioration (defined as any requirement of ventilatory support or critical care, or death) and mortality, incorporating predefined subgroups.
Results: 76 588 participants were included, of whom 27 352 (37.4%) deteriorated and 12 581 (17.4%) died. Both the 4C Mortality (0.78 (0.77 to 0.78)) and 4C Deterioration scores (pooled C-statistic 0.76 (95% CI 0.75 to 0.77)) demonstrated consistent discrimination across all nine National Health Service regions, with similar performance metrics to the original validation cohorts. Calibration remained stable (4C Mortality: pooled slope 1.09, pooled calibration-in-the-large 0.12; 4C Deterioration: 1.00, –0.04), with no need for temporal recalibration during the second UK pandemic wave of hospital admissions.
Conclusion: both 4C risk stratification models demonstrate consistent performance to predict clinical deterioration and mortality in a large prospective second wave validation cohort of UK patients. Despite recent advances in the treatment and management of adults hospitalised with COVID-19, both scores can continue to inform clinical decision making.
Trial registration number: ISRCTN66726260.
606-615
Knight, Stephen R.
cc0e7dbb-92ba-42c8-a6f1-5116ab83a6db
Gupta, Rishi K.
de1cf9ad-f52f-450b-b03b-d8bf1f44b91a
Ho, Antonia
b64267d3-f3d2-4bdc-9803-5c93be4fa90c
Dushianthan, Ahilanandan
013692a2-cf26-4278-80bd-9d8fcdb17751
ISARIC Coronavirus Clinical Characterisation Consortium (ISARIC4C) Investigators
18 October 2023
Knight, Stephen R.
cc0e7dbb-92ba-42c8-a6f1-5116ab83a6db
Gupta, Rishi K.
de1cf9ad-f52f-450b-b03b-d8bf1f44b91a
Ho, Antonia
b64267d3-f3d2-4bdc-9803-5c93be4fa90c
Dushianthan, Ahilanandan
013692a2-cf26-4278-80bd-9d8fcdb17751
Knight, Stephen R., Gupta, Rishi K. and Ho, Antonia
,
et al. and ISARIC Coronavirus Clinical Characterisation Consortium (ISARIC4C) Investigators
(2023)
Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol.
Thorax, 77, .
(doi:10.1136/thoraxjnl-2021-217629).
Abstract
Purpose: to prospectively validate two risk scores to predict mortality (4C Mortality) and in-hospital deterioration (4C Deterioration) among adults hospitalised with COVID-19.
Methods: prospective observational cohort study of adults (age ≥18 years) with confirmed or highly suspected COVID-19 recruited into the International Severe Acute Respiratory and emerging Infections Consortium (ISARIC) WHO Clinical Characterisation Protocol UK (CCP-UK) study in 306 hospitals across England, Scotland and Wales. Patients were recruited between 27 August 2020 and 17 February 2021, with at least 4 weeks follow-up before final data extraction. The main outcome measures were discrimination and calibration of models for in-hospital deterioration (defined as any requirement of ventilatory support or critical care, or death) and mortality, incorporating predefined subgroups.
Results: 76 588 participants were included, of whom 27 352 (37.4%) deteriorated and 12 581 (17.4%) died. Both the 4C Mortality (0.78 (0.77 to 0.78)) and 4C Deterioration scores (pooled C-statistic 0.76 (95% CI 0.75 to 0.77)) demonstrated consistent discrimination across all nine National Health Service regions, with similar performance metrics to the original validation cohorts. Calibration remained stable (4C Mortality: pooled slope 1.09, pooled calibration-in-the-large 0.12; 4C Deterioration: 1.00, –0.04), with no need for temporal recalibration during the second UK pandemic wave of hospital admissions.
Conclusion: both 4C risk stratification models demonstrate consistent performance to predict clinical deterioration and mortality in a large prospective second wave validation cohort of UK patients. Despite recent advances in the treatment and management of adults hospitalised with COVID-19, both scores can continue to inform clinical decision making.
Trial registration number: ISRCTN66726260.
Text
606.full
- Version of Record
More information
Accepted/In Press date: 11 October 2021
e-pub ahead of print date: 22 November 2021
Published date: 18 October 2023
Identifiers
Local EPrints ID: 495359
URI: http://eprints.soton.ac.uk/id/eprint/495359
ISSN: 0040-6376
PURE UUID: ca180ba0-5dd3-4d27-aff1-4bd0f1b7b10e
Catalogue record
Date deposited: 11 Nov 2024 18:17
Last modified: 12 Nov 2024 03:00
Export record
Altmetrics
Contributors
Author:
Stephen R. Knight
Author:
Rishi K. Gupta
Author:
Antonia Ho
Author:
Ahilanandan Dushianthan
Corporate Author: et al.
Corporate Author: ISARIC Coronavirus Clinical Characterisation Consortium (ISARIC4C) Investigators
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics